Navigation Links
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
Date:5/2/2013

ay not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law. Contact: Arena Pharmaceuticals, Inc.Media Contact: Russo PartnersCindy McGee, Vice President,

David Schull, PresidentInvestor Relations & Alliance Managementdavid.schull@russopartnersllc.comcmcgee@arenapharm.com  

858.717.2310858.453.7200, ext. 1479  Arena Pharmaceuticals, Inc.Condensed Consolidated Statements of Operations(In thousands, except per share amounts)Three months ended

March 31,20132012(unaudited)RevenuesManufacturing services

$  765$  1,292Collaborative agreements

1,608897  Total revenues

2,3732,189Operating ExpensesCost of manufacturing services

1,645791Cost of products sold

4730Research & development

14,00814,470General & administrative

7,2516,355Amortization of acquired technology & other intangibles

0176  Total operating expenses

23,37721,792Interest & Other Income (Expense)Interest income

2415Interest expense

(1,787)(3,031)Gain (Loss) from valuation of derivative liabilities

3,859(2,375)Loss on extinguishment of debt

0(1,670)Other

3287  Total interest & other income (expense), net

2,128(6,974)Net loss

(18,876)(26,577)Deemed div
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena Pharmaceuticals Announces First Quarter 2012 Financial Results and Recent Developments
2. Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
3. Arena Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
4. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
5. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
6. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
7. Arena Pharmaceuticals Files Marketing Authorization Application in Switzerland for Lorcaserin as a Treatment for Weight Control
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
9. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
10. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
11. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... VALLEY, Calif. , May 4, 2015 ... biologic for psoriasis, today announced that preclinical and mechanism ... session at the Society of Investigative Dermatology (SID) Annual ... Atlanta, in Atlanta, Georgia . ... is advancing the development of RON2315, a novel, low ...
(Date:5/4/2015)...   HeartWare International, Inc . (NASDAQ: HTWR ), ... that are revolutionizing the treatment of advanced heart failure, today ... scheduled to present at the Bank of America Merrill Lynch ... on Thursday, May 14, 2015, at 10:00 a.m. PT ... Company,s presentation at the conference will be available via a ...
(Date:5/4/2015)... , May 4, 2015 Unchained Labs, a ... to this year,s PEGS conference and launches the UNit ... for biologics. PEGS: The Essential Protein Engineering Summit takes ... 2015. The UNit lets drug discovery researchers ... tool out there. Its 7 applications, 144 sample a ...
Breaking Medicine Technology:Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2Unchained Labs Lets the UNit Loose 2
... Ambrx Inc. today announced that Ho Cho, Ph.D., ... from the company,s antibody drug conjugate (ADC) programs at ... obtained from recent xenograft studies comparing Ambrx ADCs with ... technology has been clinically validated as safe and efficacious ...
... 22, 2011 Naurex Inc., a clinical-stage ... psychiatry and neurology, today announced that it has initiated ... GLYX-13.  GLYX-13, a Glycine-site Functional Partial Agonist (GFPA) selective ... developed as a therapy for patients who are not ...
Cached Medicine Technology:Ambrx to Present Data from Antibody Drug Conjugate Program at Upcoming Scientific Conferences 2Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 2Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 3
(Date:5/4/2015)... Now in its seventh year, the IPC ... made outstanding contributions to the company, to their facilities ... and post-acute care settings. The five award categories are: ... Year, Advanced Practice Clinician of the Year, Newcomer Provider ... Recipients are selected by IPC’s senior management team. , ...
(Date:5/4/2015)... 04, 2015 EyeCRO LLC and NeuMedics ... facilitate development of NM108, a first-in-class small molecule to ... blindness, including Diabetic Retinopathy. The collaboration grants NeuMedics ... EyeCRO, which can deliver drugs to the front and ... , Under the terms of the agreement, EyeCRO will ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Ticket Down is ... the Colonial Life Arena in Columbia, South Carolina. ... continuation of his “Out There” tour which originally kicked off ... tour is North America and the legendary performer recently announced ... the Wells Fargo Arena on June 21st, in Charlottesville, VA ...
(Date:5/4/2015)... UT (PRWEB) May 04, 2015 Pricing ... (up to $3,000) of one patient receiving care at ... Utah. The procedure must be performed by July 15th, ... to pay in full up front and forego the filing ... becomes more economically burdensome every year, and it devastates more ...
(Date:5/4/2015)... Atlanta, GA (PRWEB) May 04, 2015 ... in Atlanta, Georgia proudly offers the latest non-surgical double-chin ... the only facial plastic surgeon in Atlanta to offer ... Kybella drug to be injected specifically under the chin, ... ‘double-chin’ appearance. , Before Kybella, patients who sought immediate ...
Breaking Medicine News(10 mins):Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 3Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2
... 10 Charlotte,s VR Mergers and,Acquisitions has just ... fixture in Laurinburg, NC. VR Charlotte links business ... the transaction were,not disclosed., Established in 1965, ... there since it opened. Todd, the owner since ...
... AURORA, Ohio, Dec. 10 PartsSource, the nation,s ... equipment has,been recognized as a 2007 Pillar Award ... to companies that have distinguished themselves,through leading by ... others., "My initial vision for PartsSource was ...
... (Dec. 10, 2007) Climate change will affect national ... world, in some cases altering conditions so severely that ... planet, according to a study presented at the U.N. ... International (CI), the University of Wisconsin and the University ...
... Institute researcher Jeff Tyner, Ph.D., has created a way to ... myeloid leukemia using an assay that yields results in just ... Society of Hematology annual meeting in Atlanta, on Monday, Dec. ... assay, called RAPID, because it rapidly delivers the information, has ...
... (Amex: ANX ), a biopharmaceutical research and ... the treatment,of cancer and infectious diseases, announced today ... scheduled to present at the 2007 RBC,Capital Markets ... Better Drugs &,Novel Approaches To Cancer Therapy on ...
... Resources Professional Brings Diverse Expertise, MIAMI, Dec. ... products to healthcare providers, is pleased,to announce that ... President of,Human Resources. Ms. Lopez was most recently ... Johnson Company. Her 17-year career began,in Human Resources ...
Cached Medicine News:Health News:New study shows world's protected areas threatened by climate change 2Health News:OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia 2Health News:ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference 2Health News:Novis Pharmaceuticals Hires Lisa Lopez 2
... Chart Manager information can be input ... are not limited to drop-down lists ... each person to document individually. Patient ... valuable data and communication. All this ...
AllMeds was the first specialty-specific Electronic Medical Record for Orthopaedics. Instead of trying to force a general-purpose EMR into your practice, AllMeds starts with clinical content from Ort...
... software It runs over hospital ... PAS systems and some items ... collects data at initial consultation, ... checks, operation, post-op checks, telephone ...
... such as prescription writing, referral letters, chart ... will be ,able to add more appointments ... staff., Based on the exam documentation created ... recommend the appropriate E&M ,code for the ...
Medicine Products: